KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $133.8 million.

  • Halozyme Therapeutics' Cash & Equivalents rose 1551.14% to $133.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $133.8 million, marking a year-over-year increase of 1551.14%. This contributed to the annual value of $133.8 million for FY2025, which is 1551.14% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Cash & Equivalents is $133.8 million, which was up 1551.14% from $419.7 million recorded in Q3 2025.
  • Halozyme Therapeutics' Cash & Equivalents' 5-year high stood at $499.4 million during Q1 2021, with a 5-year trough of $61.9 million in Q2 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $159.5 million (2024), whereas its average is $213.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 64790.92% in 2021, then tumbled by 7965.57% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Cash & Equivalents (Quarter) stood at $118.7 million in 2021, then surged by 97.27% to $234.2 million in 2022, then tumbled by 49.46% to $118.4 million in 2023, then dropped by 2.13% to $115.8 million in 2024, then rose by 15.51% to $133.8 million in 2025.
  • Its Cash & Equivalents stands at $133.8 million for Q4 2025, versus $419.7 million for Q3 2025 and $61.9 million for Q2 2025.